Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...

Lilly dominates GLP-1 market but faces near-term headwinds, while AstraZeneca boasts steady growth, rising estimates and a higher dividend yield.

Thai healthcare solutions company Zuellig Pharma has announced that Mounjaro (tirzepatide), Eli Lilly’s (NYSE: LLY) ...

Zuellig Pharma introduces Eli Lilly’s innovative obesity and diabetes medicine, Mounjaro in Thailand: Bangkok, Thailand Thursday, May 29, 2025, 11:00 Hrs [IST] Zuellig Pharma, a ...

Eli Lilly & Co. (LLY) shares have come under significant pressure in late May following a pivotal decision by CVS Health's ...

Zuellig Pharma, a leading healthcare solutions company in Asia, has announced that Mounjaro® (tirzepatide), the innovative obesity and diabetes medicine developed by Eli Lilly and Company, will be ...

Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural ...

In the marketing effort promoting Lilly’s Mounjaro, Stonestreet and his mother, Jamey, discuss living with type 2 diabetes and taking the GLP-1 for treatment.

With a market cap of $681.8 billion, Eli Lilly and Company (LLY) is a leading global pharmaceutical company focused on ...

Eli Lilly (NYSE: LLY) is one of the undisputed leaders in developing anti-obesity medicines, with Novo Nordisk (NYSE: NVO) ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.